Nicholas breaks down the 503A categories, the April removal of 12 peptides from Category 2, the July advisory votes, and the long rulemaking road before any pharmacy can legally compound them.
Read the full post: FDA's 2026 peptide compounding changes, explained
In this episode
- 00:00 Cold open and intro
- 00:36 Compounding primer: the 503A categories
- 01:01 April 2026: 12 peptides leave Category 2
- 01:23 July 2026: the advisory committee votes
- 01:50 What a yes vote does and doesn't mean
- 02:14 Why the FDA staff said no
- 02:39 What this means for you
- 02:54 Wrap-up and Amino Club code
Peptides covered
Tools and deals
- Free reconstitution and dosing calculator: mypeps.info/calculator
- Amino Club: 40% off with code MYPEPSINFO at aminoclub.com
Sources
- https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- https://www.orrick.com/en/Insights/2026/04/FDA-Announces-Removal-of-12-Peptides-from-Category-2-and-Schedules-PCAC-Meetings
- https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/
- https://www.pharmacytimes.com/view/what-the-peptide-vote-actually-changes-at-my-counter-hint-not-much-yet-
- Full source list in the blog post.
Educational information only, not medical advice. Talk to a licensed clinician before starting, stopping or changing any medication. Research-grade peptides are not FDA-approved drugs.